« Home | Plaintiffs Wanted for New Lawsuit - AVIP » | Review ordered for anthrax vaccine refusers » | Biolab Risks » | Corps to track anthrax refusal discharges » | Vets' Lawsuit Opens Door on Suicides, Poor Care » | Military medical malpractice: Seeking recourse » | Veteran Battles Pentagon's Vaccine, Seeks "Justice... » | FBI Focusing on 'About Four' Suspects in 2001 Anth... » | Judge advances anthrax vaccine refusal case » | Judge Keeps Anthrax Suit Alive »

VaxGen sells anthrax vaccine candidate to Emergent BioSolutions


SOUTH SAN FRANCISCO, CA (Thomson Financial) - Biopharmaceutical company VaxGen Inc. said it has completed the sale of all assets and rights related to its recombinant protective antigen (rPA) anthrax vaccine product candidate and related technology to Emergent BioSolutions Inc. Under the terms of the transaction, Emergent BioSolutions paid VaxGen an initial $2 million and may be obligated to pay up to an additional $8 million in milestone payments, plus specified percentages of future net sales.